Resolute Advisors LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Resolute Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 76.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,363 shares of the company’s stock after purchasing an additional 1,022 shares during the period. Resolute Advisors LLC’s holdings in Johnson & Johnson were worth $342,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of JNJ. Yoffe Investment Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $746,000. Annis Gardner Whiting Capital Advisors LLC increased its position in shares of Johnson & Johnson by 4.1% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 14,751 shares of the company’s stock worth $2,133,000 after purchasing an additional 576 shares in the last quarter. Atlas Capital Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 9,344.3% in the 4th quarter. Atlas Capital Advisors Inc. now owns 5,761 shares of the company’s stock valued at $833,000 after purchasing an additional 5,700 shares during the last quarter. Climber Capital SA acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $303,000. Finally, Grant Private Wealth Management Inc acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $306,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on JNJ. Bank of America increased their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley lowered their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Finally, Stifel Nicolaus reduced their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Price Performance

JNJ stock opened at $159.90 on Friday. The stock’s 50 day moving average is $159.63 and its two-hundred day moving average is $156.01. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a market capitalization of $385.33 billion, a PE ratio of 24.04, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.